These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28780601)

  • 1. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
    Taniguchi Y; Tanaka H; Luis EJ; Sakai K; Kumode T; Sano K; Serizawa K; Rai S; Morita Y; Hanamoto H; Tsubaki K; Nishio K; Matsumura I
    Int J Hematol; 2017 Nov; 106(5):691-703. PubMed ID: 28780601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.
    Aswad MH; Kissová J; Rihova L; Zavrelova J; Ovesná P; Penka M
    Klin Onkol; 2019; 32(2):109-116. PubMed ID: 30995850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing procoagulant activity of circulating microparticles in patients with Philadelphia-negative myeloproliferative neoplasms: a single-centre experience.
    Kissova J; Ovesna P; Bulikova A; Zavřelova J; Penka M
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):448-53. PubMed ID: 25828967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
    Duchemin J; Ugo V; Ianotto JC; Lecucq L; Mercier B; Abgrall JF
    Thromb Res; 2010 Sep; 126(3):238-42. PubMed ID: 20656333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients.
    Baccouche H; Ben Jemaa M; Chakroun A; Chadi S; Mahjoub S; Sfar I; Gorgi Y; Ben Romdhane N
    Int J Lab Hematol; 2017 Oct; 39(5):502-507. PubMed ID: 28497580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Aswad MH; Kissova J; Ovesna P; Rihova L; Penka M
    In Vivo; 2021; 35(6):3345-3353. PubMed ID: 34697168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms.
    Marin Oyarzún CP; Carestia A; Lev PR; Glembotsky AC; Castro Ríos MA; Moiraghi B; Molinas FC; Marta RF; Schattner M; Heller PG
    Sci Rep; 2016 Dec; 6():38738. PubMed ID: 27958278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.
    Ianotto JC; Couturier MA; Galinat H; Mottier D; Berthou C; Guillerm G; Lippert E; Delluc A
    Int J Hematol; 2017 Oct; 106(4):517-521. PubMed ID: 28623609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microparticles from splenectomized β-thalassemia/HbE patients play roles on procoagulant activities with thrombotic potential.
    Klaihmon P; Phongpao K; Kheansaard W; Noulsri E; Khuhapinant A; Fucharoen S; Morales NP; Svasti S; Pattanapanyasat K; Chaichompoo P
    Ann Hematol; 2017 Feb; 96(2):189-198. PubMed ID: 27900452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombosis in myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in response to antiaggregatory treatment in patients with myeloproliferative neoplasms: a sequential study using multiple electrode aggregometry.
    Robier C; Stettin M; Neubauer M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):869-73. PubMed ID: 24176950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of circulating microparticles in Ph
    Zhang W; Qi J; Zhao S; Shen W; Dai L; Han W; Huang M; Wang Z; Ruan C; Wu D; Han Y
    Oncol Lett; 2017 Aug; 14(2):2531-2536. PubMed ID: 28789461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.
    Mahé K; Delluc A; Chauveau A; Castellant P; Mottier D; Dalbies F; Berthou C; Guillerm G; Lippert E; Ianotto JC
    Ann Hematol; 2018 Jan; 97(1):101-107. PubMed ID: 29164292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microparticles (MPs), tissue factor (TF) and tissue factor inhibitor (TFPI) in cord blood plasma. A preliminary study and literature survey of procoagulant properties of MPs.
    Uszyński M; Zekanowska E; Uszyński W; Kuczyński J; Zyliński A
    Eur J Obstet Gynecol Reprod Biol; 2011 Sep; 158(1):37-41. PubMed ID: 21664032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombotic disease in the myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Hematology Am Soc Hematol Educ Program; 2012; 2012():571-81. PubMed ID: 23233637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease.
    Kambas K; Chrysanthopoulou A; Vassilopoulos D; Apostolidou E; Skendros P; Girod A; Arelaki S; Froudarakis M; Nakopoulou L; Giatromanolaki A; Sidiropoulos P; Koffa M; Boumpas DT; Ritis K; Mitroulis I
    Ann Rheum Dis; 2014 Oct; 73(10):1854-63. PubMed ID: 23873874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.
    Campello E; Spiezia L; Radu CM; Bulato C; Castelli M; Gavasso S; Simioni P
    Thromb Res; 2011 May; 127(5):473-7. PubMed ID: 21256535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia.
    Gheldof D; Haguet H; Dogné JM; Bouvy C; Graux C; George F; Sonet A; Chatelain C; Chatelain B; Mullier F
    J Thromb Thrombolysis; 2017 Feb; 43(2):224-232. PubMed ID: 28074413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue-factor-bearing microparticles (MPs-TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs-TF generation.
    Świtońska M; Słomka A; Sinkiewicz W; Żekanowska E
    Eur J Neurol; 2015 Feb; 22(2):395-401, e28-9. PubMed ID: 25370815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.